Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Utility of voriconazole therapeutic drug monitoring: a meta-analysis

ML. Luong, M. Al-Dabbagh, AH. Groll, Z. Racil, Y. Nannya, D. Mitsani, S. Husain,

. 2016 ; 71 (7) : 1786-99. [pub] 20160510

Language English Country England, Great Britain

Document type Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17013864

BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. We conducted a meta-analysis of studies assessing the relationship between voriconazole serum concentration and clinical outcomes of success and toxicity. METHODS: We searched bibliographic databases for studies on voriconazole serum concentrations and clinical outcomes. We compared success outcomes between patients with therapeutic and subtherapeutic voriconazole serum concentrations, and toxicity outcomes between patients with and without supratherapeutic serum concentrations. RESULTS: Twenty-four studies were analysed. Pooled analysis for efficacy endpoint demonstrated that patients with therapeutic voriconazole serum concentrations (1.0-2.2 mg/L) were more likely to have successful outcomes compared with those with subtherapeutic voriconazole serum concentrations (OR 2.30; 95% CI 1.39-3.81). A therapeutic threshold of 1.0 mg/L was most predictive of successful outcome (OR 1.94; 95% CI 1.04-3.62). Patients with therapeutic concentrations did not have better survival rates. Pooled analysis for toxicity endpoint demonstrated that patients with supratherapeutic voriconazole serum concentrations (4.0-6.0 mg/L) were at increased risk of toxicity (OR 4.17; 95% CI 2.08-8.36). A supratherapeutic threshold of 6.0 mg/L was most predictive of toxicity (OR 4.60; 95% CI 1.49-14.16). CONCLUSIONS: Patients with therapeutic voriconazole serum concentrations were twice as likely to achieve successful outcomes. The likelihood of toxicity associated with supratherapeutic voriconazole serum concentrations was 4-fold that of therapeutic concentrations. Our findings suggest that the use of voriconazole TDM to aim for serum concentrations between 1.0 and 6.0 mg/L during therapy may be warranted to optimize clinical success and minimize toxicity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013864
003      
CZ-PrNML
005      
20170426102246.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jac/dkw099 $2 doi
035    __
$a (PubMed)27165788
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Luong, Me-Linh $u Department of Infectious Diseases and Medical Microbiology, Centre Universitaire de l'Université de Montréal (CHUM), University of Montréal, Montréal, Quebec, Canada me-linh.luong.chum@ssss.gouv.qc.ca.
245    10
$a Utility of voriconazole therapeutic drug monitoring: a meta-analysis / $c ML. Luong, M. Al-Dabbagh, AH. Groll, Z. Racil, Y. Nannya, D. Mitsani, S. Husain,
520    9_
$a BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. We conducted a meta-analysis of studies assessing the relationship between voriconazole serum concentration and clinical outcomes of success and toxicity. METHODS: We searched bibliographic databases for studies on voriconazole serum concentrations and clinical outcomes. We compared success outcomes between patients with therapeutic and subtherapeutic voriconazole serum concentrations, and toxicity outcomes between patients with and without supratherapeutic serum concentrations. RESULTS: Twenty-four studies were analysed. Pooled analysis for efficacy endpoint demonstrated that patients with therapeutic voriconazole serum concentrations (1.0-2.2 mg/L) were more likely to have successful outcomes compared with those with subtherapeutic voriconazole serum concentrations (OR 2.30; 95% CI 1.39-3.81). A therapeutic threshold of 1.0 mg/L was most predictive of successful outcome (OR 1.94; 95% CI 1.04-3.62). Patients with therapeutic concentrations did not have better survival rates. Pooled analysis for toxicity endpoint demonstrated that patients with supratherapeutic voriconazole serum concentrations (4.0-6.0 mg/L) were at increased risk of toxicity (OR 4.17; 95% CI 2.08-8.36). A supratherapeutic threshold of 6.0 mg/L was most predictive of toxicity (OR 4.60; 95% CI 1.49-14.16). CONCLUSIONS: Patients with therapeutic voriconazole serum concentrations were twice as likely to achieve successful outcomes. The likelihood of toxicity associated with supratherapeutic voriconazole serum concentrations was 4-fold that of therapeutic concentrations. Our findings suggest that the use of voriconazole TDM to aim for serum concentrations between 1.0 and 6.0 mg/L during therapy may be warranted to optimize clinical success and minimize toxicity.
650    _2
$a antifungální látky $x škodlivé účinky $x krev $x terapeutické užití $7 D000935
650    12
$a monitorování léčiv $7 D016903
650    _2
$a lidé $7 D006801
650    _2
$a invazivní mykotické infekce $x farmakoterapie $x prevence a kontrola $7 D000072742
650    _2
$a mykózy $x farmakoterapie $7 D009181
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vorikonazol $x škodlivé účinky $x krev $x terapeutické užití $7 D065819
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Al-Dabbagh, Mona $u Division of Infectious Diseases, Department of Medicine, University of Toronto, University Health Network, Toronto, Ontario, Canada Department of Pediatric, Division of Infectious Diseases, King AbdulAziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Jeddah. Saudi Arabia. $7 gn_A_00003627
700    1_
$a Groll, Andreas H $u Infectious Disease Research Program, Centre for Bone Marrow Transplantation and Department of Pediatric Haematology/Oncology, University Children's Hospital Münster, Münster, Federal Republic of Germany.
700    1_
$a Racil, Zdenek $u Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Nannya, Yasuhito $u Department of Haematology and Oncology, Graduate School of Medicine, The University of Tokyo, Japan.
700    1_
$a Mitsani, Dimitra $u Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Husain, Shahid $u Division of Infectious Diseases, Department of Medicine, University of Toronto, University Health Network, Toronto, Ontario, Canada.
773    0_
$w MED00002514 $t The Journal of antimicrobial chemotherapy $x 1460-2091 $g Roč. 71, č. 7 (2016), s. 1786-99
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27165788 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170426102604 $b ABA008
999    __
$a ok $b bmc $g 1200329 $s 974642
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 71 $c 7 $d 1786-99 $e 20160510 $i 1460-2091 $m Journal of antimicrobial chemotherapy $n J Antimicrob Chemother $x MED00002514
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Archiving options